High tibial osteotomy (HTO) is a recognised method of correction for knee joint malalignment and unicompartmental osteoarthritis. The long term results of this technique have been reported and are favourable. Autologous chondrocyte implantation (ACI-C, MACI) has also been reported to have good results It is advised that malalignment, if present, should be corrected if ACI is to be performed. Although results have been reported for either procedure separately, the outcomes of combined HTO-ACI remain unreported.

To evaluate functional outcome in a group of patients undergoing combined HTO-ACI procedures.

Twenty three patients undergoing a combined ACI-HTO procedure were identified retrospectively from a larger trial of patients undergoing ACI for symptomatic chondral defects. The mean follow-up was 54 months (range 12 – 108) and the mean defect size was 689 mm2 (range 350 – 1200). Nine patients had ACI-C and HTO, the remainder having MACI and HTO. Pre and postoperative assessment was carried out using the Visual Analogue Score (VAS), the Bentley Functional Rating Score and the Modified Cincinnati Rating System.

The Mean VAS score improved from 7.4 pre-operatively to 2.9 post-operatively (p< 0.0001). The Bentley Functional Rating Score improved from 2.9 to 1.8 (p< 0.0001) whilst the Modified Cincinnati Rating System improved from 35.2 pre-operatively to 68.7 post-operatively (p< 0.0001). There was no significant difference between ACI-C and MACI. Two patients developed a non union at a mean of 13 months and a further two patients had a failure of the chondrocyte graft at a mean of 22.5 months.

Combining high tibial osteotomy with autologous chondrocyte implantation is an effective method of decreasing pain and increasing function at mean of 54 months follow-up. Further follow-up is required to assess the long term outcomes of these combined procedures.

Non-bacterial osteitis (NBO), a term referring to sterile bone lesions with non-specific histopathological features of inflammation, may be either uni- or multifocal, acute (6 months) or chronic, and recurrent. Only when the condition is chronic, recurrent and multifocal is it appropriate to use the term chronic recurrent multifocal osteomyelitis (CRMO).

We present our clinical experience as the largest reported series of children with NBO to date. Of 41 children (2–16 years) diagnosed with NBO in our institution over the last 6 years, 21 (51%) had recurrent disease and 18 of 41 (44%) had multifocal disease. The most common bones affected were the clavicle, femur and tibia (in order of decreasing prevalence) accounting for 44 (63%) of a total of 70 lesions. Only one individual had SAPHO syndrome and no other patients had evidence of bowel or skin disease. In the absence of evidence for an infective aetiology, we recommend non-steroidal anti-inflammatory agents as first line therapy, and bisphosphonates only in cases of resistant disease.

On the basis of our findings we propose a patient questionnaire and protocol for investigating and managing patients who present to orthopaedic surgeons with NBO. We predict that this will benefit patients with this disorder by providing valuable information about the pathogenesis, clinical outcome and response to treatment. In the future, clarification of the pathogenesis of this disease will undoubtedly help rationalise the therapeutic approach improving both quality of life and outcome for these patients.

Introduction: Initial results for the management of osteochondral defects with both ACI-C and MACI have been encouraging, showing significant clinical improvements. This study set out to report the functional, clinical and histological outcomes in our institution following nine years experience of cartilage-cell transplants.

Aim: Reporting results of nine-year experience of clinical and arthroscopic assessment in the use of ACI and five year experience of MACI in the management of symptomatic, full-thickness chondral and osteochondral defects in the knee.

Method: Following preoperative functional assessments, arthroscopic harvesting of chondrocytes for culture was performed and patients underwent ACI-C or MACI. In ACI-C a covered technique is employed using a porcine-derived type I/III collagen membrane sutured in place; MACI requires cultured autologous chondrocytes to be seeded in a bi-layered type I/III collagen membrane which is glued into position. An arthroscopy was performed between 12 and 24 months post-procedure to assess graft coverage and biopsies taken to determine extent of hyaline, mixed and fibro-cartilage proliferation.

Results: 354 patients underwent either ACI-C (103) or MACI (251) with an average age of 31.3 (15–54). Cincinnati knee rating scores recorded prior to assessment arthroscopy for ACI-C: 58.6 (12 – 92) and MACI: 48.4 (11 – 90) showed improvement at follow up with means of 84.0 for ACI-C, with 78% of patients scoring good or excellent at nine years, and a mean of 82.3% in the MACI group at five years, with 87% of patients recording good or excellent scores; statistically significant improvement was also noted in Bentley Functional score. Biopsies of the transplants taken between 12 and 24 months revealed proliferation of hyaline and mixed cartilage (hyaline and fibro-cartilage) in 47% patients; the later the biopsy was taken post-implantation, it was more likely to reveal hyaline tissue.

Conclusion: Results to date suggest significant clinical and arthroscopic improvement following ACI-C and MACI, with evidence of proliferation of hyaline cartilage at the transplant site and evidence to suggest dynamic improvement in hyaline-nature of cartilage. Limited differences are noted between the outcomes of the two techniques.

Introduction: Autologous Chondrocyte Implantation (ACI) is a treatment option for full-thickness chondral, or osteochondral injuries that are painful and debilitating. Goals of surgery and rehabilitation include replacement of damaged cartilage with hyaline or hyaline-like cartilage, leading eventually to improved level of function. Intermediate and long-term results are promising in terms of functional and clinical improvement.

Purpose: To explore the hypothesis that the quality of the repair tissue, formed following Autologous Chondrocyte Implantation (ACI), improves with time post-surgery.

Methods and Results: Two hundred and forty eight patients who underwent autologous chondrocyte implantation in our institution were studied after having had post implantation biopsies of the repair tissue. Mean timing of biopsy was 14.8 months (range 3–55). 59 biopsies gave hyaline tissue (24%), 67 mixed hyaline and fibrocartilage (27%), 113 biopsies were fibrocartilage only (46%) and 9 patients had a fibrous tissue biopsy result (9%). Due to NHS restraints and waiting list targets biopsies were actually performed at various time points post implantation allowing us to statistically correlate histological findings with the maturity of the repair tissue.

Our statistical analysis suggests that if time post implantation doubles then the likelihood of a favourable histological outcome increases significantly.

Conclusion: Autologous chondrocyte implantation forms a durable repair tissue that remodels and continues to improve in quality with time. It is recommended that for future research/study purposes 24 months is used as an optimal time to look at histology, since our data show that outcome is still improving until this point.

Introduction: Initial results for the management of osteochondral defects with both ACI-C and MACI have been encouraging, showing significant clinical improvement. This single-centre study set out to determine any significant difference in outcomes between ACI-C and MACI.

Aim: Reporting three year follow up of clinical and arthroscopic assessment of prospective analysis of ACI-C and MACI used in the management of symptomatic, full-thickness chondral and osteochondral defects in the knee.

Method: Following assessment arthroscopy and harvesting of chondrocytes for culture, patients were randomised into the ACI-C or MACI arm and underwent their respective procedures one month later. In ACI-C a covered technique is employed using a porcine-derived type I/III collagen membrane sutured in place; MACI requires cultured autologous chondrocytes to be seeded in a bi-layered type I/III collagen membrane which is glued into position. An arthroscopy was performed at 12 and 24 months postprocedure to assess graft coverage and biopsies taken to determine extent of hyaline, mixed and fibro-cartilage proliferation.

Results: 102 patients underwent either ACI-C (44) or MACI (58) with an average age of 33.6 (14–52). Mean Cincinnati knee rating scores recorded prior to assessment arthroscopy for ACI-C: 45.2 (10 – 94) and MACI: 45.5 (10 – 90) showed improvement at follow up with 63% of patients in the ACI-C group scoring good or excellent at three years, and 60% in the MACI group. ICRS arthroscopy scores were good or excellent in 91.4% of ACI-C and 76.1% of MACI patients at 24 months. Biopsies of the transplants at 24 months revealed proliferation of hyaline and mixed cartilage (hyaline and fibro-cartilage) in 48.6% of the ACI-C and 30.5% of the MACI patients.

Conclusion: Results to date suggest significant clinical and arthroscopic improvement following ACI-C and MACI, with evidence of proliferation of hyaline cartilage at the transplant site. Limited differences are noted between the outcomes of the two techniques.

Introduction: The use of custom made CAD-CAM femoral stems in primary Total Hip Replacement allows preservation of valuable bone stock in anatomically challenging femora whilst optimising biomechanics and improving function. The custom prosthesis design and manufacturing process is carried out with the aid of computed tomography (CT), a system of tomographic image processing, a Computer–Aided Design (CAD) system and a Computer–Aided Manufacturing (CAM) system.

Aim: To report seven year minimum follow up of a custom made and designed femoral component used in total hip replacement, focusing on clinical and radiographic evidence of failure.

Methods: Patients who had an uncemented total hip arthroplasty, by one of the two senior authors, with a CAD-CAM hip between February 1993 and February 2000 were retrospectively studied. An independent observer evaluated all patients radiologically using Engh’s criteria of osteointegration and clinically using Harris and Oxford Hip Scores.

Results: 85 patients (47 male, 38 female) (102hips) underwent THA for a variety of reasons between February 1993 and February 2000. Average age was 53.7 (25.4–91.5). Average follow up was 9.3 years (7–15). The aetiologies for THA were: Developmental Dysplasia of Hip (22 hips), Osteoarthritis (25), Slipped Upper Femoral Epiphysis (3), Skeletal Dysplasia (11), Trauma (9), Perthe’s Disease (6), Avascular Necrosis (14), Tumour (4) and other (8). At last follow up 4 hips had been revised: 2 for aseptic loosening, 1 for deep infection and 1 for excessive acetabular cup liner wear. 84 patients were evaluated (one deceased from unrelated causes). Average Harris Hip Score was 81 (range 53–96). Average Oxford Hip Score was 24 (range15–43). A full set of x-rays was available for 73 patients and when evaluated all were radiographically stable. Endosteal bone formation or spots welds were present on all 73 of the x-rays. Radiolucent lines at the bone-implant interface were present on 7/73 x-rays but did not correlate with clinical problems. There was no evidence of bone pedestal formation.

Conclusions: Clinical results are good to excellent with little radiographic evidence of failure. CAD-CAM hips can be safely and reliably used for a variety of aetiologies with predictable result at least up to seven years postoperatively.

We retrospectively studied 67 patients who underwent proximal humeral replacement with the Bayley-Walker prosthesis, for tumour of the proximal humerus between 1997 and 2007. Of the 67 patients 10 were lost to follow up. Of the 41 surviving patients, function was assessed using the Musculoskeletal Tumour Society (MSTS) Score and the Toronto Extremity Salvage Score (TESS) questionnaire.

4 of the 41 patients received the new Bayley-Walker ‘captured’ proximal humeral replacement. The mean age was 46 years (7–87). The mean MSTS score at follow-up was 72.0 % and the mean TESS score was 77.2 %. The sub-group of 4 pts who received the new captured prosthesis had a mean MSTS score of 77.7 %. There was no mechanical failure of any prostheses in the follow up period.

Endoprosthetic replacement for tumour of the proximal humerus with the Bayley-Walker prosthesis, is a reliable operation yielding reasonable functional results and good long-term prosthesis survivorship. The performance of this prosthesis is expected to improve further with the new ‘captured’ prosthesis.

Introduction: We report our experience with use of the SMILES prosthesis in primary knee arthroplasty.

Methods: The Stanmore Modular Individualised Lower Extremity System (SMILES prosthesis) has been shown to be effective in complex revision knee surgery. It incorporates a rotating hinge platform knee joint and can overcome the major problems of bone loss and ligamentous laxity.

38 patients (41 knees) who received a primary SMILES knee prosthesis by one of the senior authors between 1990 and 2006 were retrospectively studied. Knee function was assessed pre and post-operatively using the Oxford knee score (0–48 scoring system) and the Knee Society Score. Patients receiving surgery for tumours were excluded. The main indications for primary SMILES were bone loss and ligamentous laxity.

Results: The minimum follow-up was 18 months with a mean of 5 years (1–17). The mean age of the patients was 57.7 years (23–86); 15 of the patients were male. The indications for surgery were trauma (12), osteoarthritis with deficient medial collateral ligament (8), polio (7), rheumatoid arthritis (5), epiphyseal dysplasia (4), achondroplasia (2), avascular necrosis (1), osteogenesis imperfecta (1) and ankylosing spondylitis (1).

2 patients died and 5 were lost to follow-up. 2 patients required revision surgery (one for infection and one for re-bushing). Post-operative complications included peroneal nerve palsy (1) and DVT (1). The mean Oxford knee score improved from 9 pre-op to 44 post-op, and the mean knee society score improved from 24 pre-op to 71 post-op. The average range of motion was 57 degrees pre-op and 88 degrees post-op.

Conclusion: We conclude that the SMILES prosthesis offers significant improvement in clinician and patient assessed outcome scores in complex primary knee arthroplasty. The cost compares favourably with other designs and its use is well established.